GW Pharmaceuticals up on Q3 beat

• GW Pharmaceuticals (NASDAQ:GWPH) Q3 results:
• Revenue: $137.05M (+50.7% Y/Y) vs consensus of $125.97M; Epidiolex U.S. sales: $121.6M.
• Net loss: ($12.2M) (-11.6%); loss/share: ($0.03) (-25.0%) vs consensus of ($0.06).
• Cash flow ops: ($33.31M) (-69.0%).
• Epidiolex for seizures associated with TSC launched in the U.S.
• Recruitment in Phase 3 of Nabiximols development program in MS spasticity trial under way.
• Active recruitment started in Phase 2b trial for schizophrenia (GWP42003).
• CBD formulation Phase 2 study in autism, expected to commence in Q1 2021.
• https://seekingalpha.com/news/3630338-gw-pharmaceuticals-up-6_4-on-q3-beat